The VLA/ALMA Nascent Disk and Multiplicity (VANDAM) Survey of Orion Protostars. IV. Unveiling the Embedded Intermediate-Mass Protostar and Disk within OMC2-FIR3/HOPS-370

We present ALMA (0.87 and 1.3 mm) and VLA (9 mm) observations toward the candidate intermediate-mass protostar OMC2-FIR3 (HOPS-370; L bol ∼ 314 L o˙) at ∼0.″1 (40 au) resolution for the continuum emission and ∼0.″25 (100 au) resolution of nine molecular lines. The dust continuum observed with ALMA at 0.87 and 1.3 mm resolves a near edge-on disk toward HOPS-370 with an apparent radius of ∼100 au. The VLA observations detect both the disk in dust continuum and free-free emission extended along the jet direction. The ALMA observations of molecular lines (H2CO, SO, CH3OH, 13CO, C18O, NS, and H13CN) reveal rotation of the apparent disk surrounding HOPS-370 orthogonal to the jet/outflow direction. We fit radiative transfer models to both the dust continuum structure of the disk and molecular line kinematics of the inner envelope and disk for the H2CO, CH3OH, NS, and SO lines. The central protostar mass is determined to be ∼2.5 M o˙ with a disk radius of ∼94 au, when fit using combinations of the H2CO, CH3OH, NS, and SO lines, consistent with an intermediate-mass protostar. Modeling of the dust continuum and spectral energy distribution yields a disk mass of 0.035 M o˙ (inferred dust+gas) and a dust disk radius of 62 au; thus, the dust disk may have a smaller radius than the gas disk, similar to Class II disks. In order to explain the observed luminosity with the measured protostar mass, HOPS-370 must be accreting at a rate of (1.7-3.2) × 10-5 M o˙ yr-1. © 2020. The American Astronomical Society. All rights reserved.Immediate accessThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

The VLA/ALMA Nascent Disk and Multiplicity (VANDAM) Survey of Orion Protostars. V. A Characterization of Protostellar Multiplicity

We characterize protostellar multiplicity in 20 Current address: Niels Bohr Institute, University of Copenhagen, Øster Voldgade 5a7, DK-1350, Copenhagen K, Denmark. the Orion molecular clouds using Atacama Large Millimeter/submillimeter Array 0.87 mm and Very Large Array 9 mm continuum surveys toward 328 protostars. These observations are sensitive to projected spatial separations as small as ∼20 au, and we consider source separations up to 104 au as potential companions. The overall multiplicity fraction (MF) and companion fraction (CF) for the Orion protostars are 0.30 ± 0.03 and 0.44 ± 0.03, respectively, considering separations from 20 to 104 au. The MFs and CFs are corrected for potential contamination by unassociated young stars using a probabilistic scheme based on the surface density of young stars around each protostar. The companion separation distribution as a whole is double peaked and inconsistent with the separation distribution of solar-type field stars, while the separation distribution of Flat Spectrum protostars is consistent solar-type field stars. The multiplicity statistics and companion separation distributions of the Perseus star-forming region are consistent with those of Orion. Based on the observed peaks in the Class 0 separations at ∼100 au and ∼103 au, we argue that multiples with separations 103 au to <103 au, and that some companions between 103 and 104 au must be (or become) unbound. © 2022. The Author(s). Published by the American Astronomical Society.Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

The VLA/ALMA Nascent Disk And Multiplicity (VANDAM) survey of Orion protostars. V. A characterization of protostellar multiplicity

Interstellar matter and star formatio

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron